Immuneering 2026: Revenue ($24.34M), EPS ($0.37) — 10-Q Summary
Immuneering reported a net loss of $24.19M for 2026, up 61.7% from 2025. Revenue was $24.34M, down 62.6% YoY. The company began dosing for MAPKeeper 301, increased enrollment, and plans further trials for atebimetinib combinations. Phase 2 data is expected in 2027.
How this was made
The 30-second read
Why it matters
The filing provides the first public details on trial enrollment acceleration and survival outcomes, which are material for valuation.
Market read
New financial loss and trial progress data give traders fresh information to reassess IMRX valuation.
What to watch
Potential partnership or licensing deals not disclosed yet could further influence price.
Background
Immuneering Corp filed its Q3 2026 10‑Q, reporting financial results and updates on its atebimetinib combination trials.
Ticker impact
10-Q filing shows a net loss of $24.19M and Phase 2 trial enrollment ahead of schedule with topline results expected mid‑2028.
potential modest upside on trial progress, but overall bearish pressure from the large loss.
Losses are material for a micro‑cap, yet the trial data is a primary disclosure that can move the share price.
Market effects
Biotech sector may see slight uplift as early‑stage trial data emerges.
US biotech investors likely to react; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The loss may be overstated; focus on upcoming trial data could drive a rebound.
Key entities
- companyImmuneering Corp
Biotech firm developing atebimetinib combinations.
